Our Businesses
Our Company
Share
Back to top
HIV vaccine
-
For World AIDS Day, we look at the groundbreaking strides the company has made—and continues to make—toward a world without the disease.
-
The company is proud to have placed in the top 20 on the prestigious list for its commitment to innovation, dedication to social responsibility and the quality of its products, among other noteworthy attributes—all in the face of a global pandemic.
-
The Access to Medicine Index, a ranking of pharmaceutical companies' work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company's deep history of ensuring people in underserved communities receive the treatments they need.
-
The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
-
For World AIDS Day, three attendees of the virtual 2020 International AIDS Society Conference, including activist and actress Laverne Cox, talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
-
A groundbreaking trial for an HIV vaccine. New ways to help the body heal itself. Immunotherapy treatments for cancer. Behind medical advancements like these are the brilliant scientists who are relentlessly pushing their visions and research forward.
-
From a first-of-its-kind contact lens that darkens when exposed to bright light to the first donation of 500,000 doses of an Ebola vaccine, here are just some of the ways Johnson & Johnson helped change the trajectory of health for humanity this past year.
-
Music stars. World leaders. Activists. They all came together at the Global Citizen Festival to help tackle the world's most pressing issues, including HIV. In the lead-up to the big event, we spoke to some inspiring people playing an active role in fighting the disease—and advocating for those living with it.
-
As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.
-
Announced ahead of the International AIDS Society Conference on HIV Science in Mexico City, the new study will evaluate an investigational vaccine regimen in eight countries around the world for its ability to protect people from HIV infection.
-
A study of women, by women. We're talking about the Imbokodo trial, which is evaluating an investigational HIV vaccine in sub-Saharan Africa. As the study hits a key milestone, we sat down with South African physician and scientist Glenda Gray, who's at the helm of the groundbreaking trial.
-
From breakthrough work to eradicate some of the world's deadliest diseases to advancements in cutting-edge health technology, see just some of the ways Johnson & Johnson is working to help change the trajectory of health for humanity.
-
Check out this fun interactive map for a glimpse at how the company is helping people on nearly every continent live healthier lives.
-
It's been 30 years since the first World AIDS Day was recognized. Jens Van Roey, M.D., shares how a fateful diagnosis coincidentally that same year transformed him from a humble physician into a tireless champion for those afflicted with the disease.
-
The company has secured a top ranking on the biennial report—which grades companies on their efforts to make medicine more accessible to those in low- and middle-income countries—for the fourth consecutive time.
